Real-world evidence in diagnostics and treatment of patients with multiple myeloma

Introduction. Multiple myeloma is the second most common malignant hemopathy. The average incidence of this disease in our country is 4.2-6.7/100,000 inhabitants per year. Despite significant progress in the overall survival over the past 20 years, only 10-15% of patients achieve long-term remission and an average survival that corresponds to the average life expectancy of the general human population. The current recommendations for the treatment of multiple myeloma are globally based on the results of randomized clinical trials in which only 10-40% of patients are treated, which is why the analysis of the results of the patients treated outside of randomized clinical trials, the so-called ?Real-World Evidence? data, is very important. Diagnosis and treatment of multiple myeloma - Real-World Evidence. Through presentations of the cases from routine clinical practice, multiple myeloma treatment modalities are presented in accordance with modern recommendations for diagnosis and treatment, as well as the multiple myeloma phase of the disease: treatment approach in newly diagnosed patients; treatment of the first relapse; and treatment of the second and subsequent relapses. Conclusion. The analysis of Real-World Evidence data indicates significant differences between clinical and laboratory characteristics of patients treated outside randomized clinical trials in comparison to the randomized clinical trials participants, with an significant impact to the therapeutic approach, course and outcome of the disease, consequently leading to the necessity of further Real- World Evidence analyzes and their inclusion in the current recommendations for multiple myeloma diagnosis and treatment